Pre-earnings options volume in Biomea Fusion is normal with calls leading puts 5:2. Implied volatility suggests the market is anticipating a move near 6.6%, or $1.04, after results are released. Median move over the past eight quarters is 3.5%.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on BMEA:
- Biomea Fusion presents BMF-219 data from escalation phase of COVALENT-111 trial
- Biomea Fusion Presents Patient Cohorts in COVALENT-111 Displaying a Durable Placebo-Adjusted Mean Reduction of up to 1.4% in HbA1c While Off Therapy at Week-26, after BMF-219’s 28-Day Treatment Cycle, Supporting Improved Pancreatic Function
- Biomea Fusion options imply 29.9% move in share price post-earnings
- Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
- Biomea Fusion options imply 25.3% move in share price post-earnings